Early data from the Phase III COLUMBUS study looking at a combination of Array BioPharma Inc.’s BRAF inhibitor encorafenib (LGX818) and MEK inhibitor binimetinib (MEK162) proved positive, sending the company's stock price soaring, though more information is needed to assess the competitive prospects for what would be the third BRAF/MEK inhibitor duo to market.
Top-line data from the first part of the Phase III study in patients with BRAF-mutant advanced, unresectable or metastatic melanoma...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

